GlassScriptPhysician profile
Bryan Ronn Reed
NPI 1811626187
$4,950.19
in general payments reported to CMS, 2019-2025
14 companies · $2,270 in 2025
The $2,270 reported for 2025 was more than what 94% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $787 · 2024: $1,894 · 2025: $2,270.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,839 · Education: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,838.70 |
| Education | $111.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,462.05 | 2023-2025 | |
| Teva Pharmaceuticals USA, INC. | $690.37 | 2023-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Alkermes, INC. | $505.63 | 2023-2025 | Lybalvi, Aristada |
| Otsuka America Pharmaceutical, INC. | $443.65 | 2023-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Lundbeck LLC | $432.88 | 2023-2025 | Rexulti |
| Neurocrine Biosciences, INC. | $412.02 | 2024-2025 | Ingrezza |
| Janssen Pharmaceuticals, INC | $366.01 | 2023-2025 | Spravato, Invega Sustenna |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $189.50 | 2024-2025 | Caplyta |
| Supernus Pharmaceuticals, INC. | $178.16 | 2024-2025 | Qelbree |
| Axsome Therapeutics, INC. | $166.19 | 2024-2025 | Auvelity |
| Takeda Pharmaceuticals U.S.A., INC. | $42.28 | 2023-2024 | Trintellix |
| Collegium Pharmaceutical, INC. | $33.16 | 2025 | Jornay Pm |
| Noven Therapeutics, LLC | $14.24 | 2024 | Xelstrym, Secuado |
| Azurity Pharmaceuticals, INC. | $14.05 | 2025 | Horizant |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bryan Reed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.